Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Associa...
April 10 2021 - 8:30AM
Business Wire
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, today announced a
poster presentation at the American Association for Cancer Research
(AACR) Annual Meeting 2021, being held virtually from April
10-15.
The e-poster will provide an overview of the development of
biomarker assays that are being implemented to support the DRAGON
Phase 1 proof-of-concept trial (NCT04291079). The DRAGON trial is
evaluating SRK-181, a selective inhibitor of latent TGFβ1, in
patients with locally advanced or metastatic solid tumors that have
shown primary resistance to checkpoint inhibitor therapies.
Details of the poster presentation at the meeting are as
follows:
- Title: “Development of a Comprehensive Biomarker
Strategy to Support the Latent TGFβ1 Inhibitor SRK-181 Phase 1
Clinical Trial, DRAGON” (P.1801)
- Available for on-demand viewing starting April 10, 2021 at
8:30am ET during the Modifiers of the Tumor Microenvironment
Session.
About SRK-181 SRK-181 is a selective inhibitor of TGFβ1
activation and is an investigational product candidate being
developed to overcome primary resistance to checkpoint inhibitor
therapy, such as anti-PD-(L)1 antibodies. TGFβ1 is the predominant
TGFβ isoform expressed in many human tumor types. Based on analyses
of various human tumors that are resistant to anti-PD-(L)1 therapy,
data suggest TGFβ1 is a key contributor to the immunosuppressive
microenvironment, excluding and preventing entry of cytotoxic T
cells into the tumor, thereby inhibiting anti-tumor immunity (1).
Scholar Rock believes SRK-181, which specifically targets the
latent TGFβ1 isoform, has the potential to overcome this immune
cell exclusion and induce tumor regression when administered in
combination with anti-PD-(L)1 therapy while potentially avoiding
toxicities associated with non-selective TGFβ inhibition. The
DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in
patients with locally advanced or metastatic solid tumors is
ongoing. The efficacy and safety of SRK-181 have not been
established. SRK-181 has not been approved for any use by the FDA
nor any other regulatory agency.
(1) Martin et al., Sci. Transl. Med. 12: 25 March 2020
About Scholar Rock Scholar Rock is a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative medicines for the treatment of serious diseases in
which signaling by protein growth factors plays a fundamental role.
Scholar Rock is creating a pipeline of novel product candidates
with the potential to transform the lives of patients suffering
from a wide range of serious diseases, including neuromuscular
disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to
targeting the molecular mechanisms of growth factor activation
enabled it to develop a proprietary platform for the discovery and
development of monoclonal antibodies that locally and selectively
target these signaling proteins at the cellular level. By
developing product candidates that act in the disease
microenvironment, the Company intends to avoid the historical
challenges associated with inhibiting growth factors for
therapeutic effect. Scholar Rock believes its focus on biologically
validated growth factors may facilitate a more efficient
development path. For more information, please visit
https://scholarrock.com/ or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding the potential of SRK-181 to
address certain patient unmet needs and the ability of any product
candidate to perform in humans in a manner consistent with earlier
nonclinical, preclinical or clinical trial data. The use of words
such as “may,” “might,” “will,” “should,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “project,” “intend,” “future,”
“potential,” or “continue,” and other similar expressions are
intended to identify such forward-looking statements. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
Scholar Rock’s ability to provide the financial support, resources
and expertise necessary to identify and develop product candidates
on the expected timeline, the data generated from Scholar Rock’s
nonclinical and preclinical studies and clinical trials as well as
those risks more fully discussed in the section entitled "Risk
Factors" in Scholar Rock’s Annual Report on Form 10-K for the
quarter ended December 31, 2020, as well as discussions of
potential risks, uncertainties, and other important factors in
Scholar Rock’s subsequent filings with the Securities and Exchange
Commission. Any forward-looking statements represent Scholar Rock’s
views only as of today and should not be relied upon as
representing its views as of any subsequent date. All information
in this press release is as of the date of the release, and Scholar
Rock undertakes no duty to update this information unless required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210410005013/en/
Scholar Rock: Investors/Media Catherine Hu
chu@scholarrock.com
Media: Ariane Lovell Finn Partners
ariane.lovell@finnpartners.com 917-565-2204
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024